Large pharma companies at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
11 large pharma companies are at ESGCT 2026 — 23 presentations on the program. Most represented: AstraZeneca (7 on the program), Roche (3 on the program), Boehringer Ingelheim (2 on the program). 6 of them have their own page in this guide. As of Oct 16, 2026.
Topic
Top represented
Showing 1–11 of 11 organizations
| Organization | ESGCT 2026 Attendance |
|---|---|
AstraZeneca Cambridge, UK | |
Global pharmaceutical company whose genetic medicines work includes lipid nanoparticle delivery of mRNA for gene editing. | Poster Wed Oct 28 1:30pm–3:30pm Improving prime editing with chemically modified pegRNAs Poster Wed Oct 28 1:30pm–3:30pm Precise genome editing to enable next-generation T cell therapies Poster Wed Oct 28 1:30pm–3:30pm THOR: A CRISPR–Cas9 System for Precise Templated Editing without Exogenous Polymerases Poster Thu Oct 29 2:00pm–4:00pm AAV8-mediated human ANGPTL3 expression enables rapid in vivo screening of CRISPR guide RNAs without transgenic mice Poster Thu Oct 29 2:00pm–4:00pm Precise Correction of the Sickle Cell Disease Mutation by DNA Repair Manipulation and Genome Editing in Hematopoietic Stem Cells Poster Thu Oct 29 2:00pm–4:00pm Therapeutic Genome Editing of Cystic Fibrosis using PRINS Talk Thu Oct 29 5:00pm–6:00pm Development and CMC of Lipid Nanoparticles for Non‑Viral mRNA Delivery in Gene Editing Vectors and delivery (AAV, lentiviral, LNP)Manufacturing, CMC and access |
Roche Basel, Switzerland | |
Global pharmaceutical and diagnostics group whose gene therapy research includes AAV capsids that reach the brain and drug-controlled transgene switches. | Poster Wed Oct 28 1:30pm–3:30pm Tunable gene control via RNA splicing with a clinically approved small molecule Poster Thu Oct 29 2:00pm–4:00pm Inducible gene expression switch for precise therapeutic transgene control using a clinically approved small molecule Poster Thu Oct 29 2:00pm–4:00pm Retargeting Genetically Modified AAV Capsids to the Blood-Brain Barrier |
Boehringer Ingelheim Ingelheim, Germany | |
Family-owned pharmaceutical company whose Viral Therapeutics Center develops oncolytic viruses and other virus-based therapies. | Poster Wed Oct 28 1:30pm–3:30pm Adenoviral E1 is required for efficient AAV genome replication independently of viral promoter activation Poster Wed Oct 28 1:30pm–3:30pm Split-intein selectable markers enable efficient multi-gene engineering of HEK293 suspension cells for viral vector production |
Johnson & Johnson Innovative Medicine New Brunswick, New Jersey | |
Pharmaceutical business of Johnson & Johnson, formerly Janssen, with medicines in oncology, immunology and neuroscience, including the CAR-T therapy Carvykti. | Poster Wed Oct 28 1:30pm–3:30pm From Guideline to Practice: Temperature Excursion Management Poster Thu Oct 29 2:00pm–4:00pm Assessment of shear stress induced saRNA–LNP instability for process development |
Novartis Basel, Switzerland | |
Global pharmaceutical company whose marketed products include the gene therapy Zolgensma and the CAR-T therapy Kymriah. | Talk Tue Oct 27 5:30pm–7:30pm Long-read TES to study rAAV integration: from benchmarking in clonal systems to insights in primary human hepatocytes Vectors and delivery (AAV, lentiviral, LNP) Poster Wed Oct 28 1:30pm–3:30pm Systemic immune responses in patients administered a single subretinal injection of an AAV2-based gene therapy |
Sanofi Paris, France | |
Global pharmaceutical company with programmes in rare diseases and genomic medicine. | Talk Wed Oct 28 9:30am–10:30am MADCAP: Unearthing Metagenomic AAV Caches with Deep Petascale Mining Vectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm Custom single cell RNA sequencing approach for adeno-associated virus screening to advance gene therapy using organoids and droplet microfluidics |
CSL Melbourne, Australia | |
Global biotherapeutics company whose CSL Behring unit markets Hemgenix, an AAV5 gene therapy for hemophilia B. | Poster Wed Oct 28 1:30pm–3:30pm An AAV5-hFIX-Padua single dose study of 14 month-old NHP with 2 year LTFU supports dosing of HEMGENIX® in juvenile Hemophilia B patients |
Fresenius Bad Homburg, Germany | |
Healthcare group whose Fresenius Kabi business makes biopharmaceuticals, infusion therapies and cell-processing systems used in cell and gene therapy manufacturing. | Poster Thu Oct 29 2:00pm–4:00pm EASYGEN: Developing a Scalable Framework for Hospital-Based Decentralized CAR-T Manufacturing |
JCR Pharmaceuticals Ashiya, Japan | |
Biopharmaceutical company focused on rare diseases, developing transferrin receptor-targeted enzymes and AAV vectors that cross the blood-brain barrier. | Poster Wed Oct 28 1:30pm–3:30pm Enhanced CNS gene delivery by a transferrin receptor–targeted AAV for CLN1 |
Regeneron Tarrytown, NY | |
US biopharmaceutical company making antibody medicines and developing genetic medicines, including CRISPR-based gene insertion for hemophilia B. | Talk Fri Oct 30 9:45am–10:30am Targeted Gene Insertion of Factor 9 as a Potential Durable Treatment for Hemophilia B Gene and epigenome editingRare and inherited disease |
UCB Brussels, Belgium | |
Global biopharmaceutical company focused on neurology and immunology; its gene therapy CMC teams develop AAV production processes. | Poster Thu Oct 29 2:00pm–4:00pm Optimizing transient transfection at high cell density for cost‑efficient, high‑quality rAAV production |
Instantly find 20 buyers from large pharma companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ESGCT 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction